All In MedTech

Device Trial Radar · NCT04933461

Simulated Clinical Use Testing to Evaluate Sharps Injury Prevention Features of HTL-STREFA's Safety Lancets (Test C)

Last checked: Nov 20, 2026Latest source record: Jun 21, 2021 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

20

Actual

Start

Sep 24, 2019

Primary completion

Sep 24, 2019

Study completion Sep 27, 2019

Sponsor

Lead sponsor
HTL-Strefa S.A.Not on our public-company list
Sponsor type
Industry
First posted
Jun 21, 2021

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Other
FDA-regulated device
No
Who can join
All sexes, from 18 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

A simulated clinical use testing to evaluate the Medlance Plus and myLance sharps injury prevention feature in accordance with the FDA's guidance on medical devices with sharps injury prevention features.

Conditions

  • Accident Injury

Interventions

  • Safety lancetDevice

    There are sterile, single-use safety lancets designed for the sampling of capillary blood from the fingertip of patients.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. The true failure rate of the tested devices.Time frame: At time of testing, up to 90 minutes
  2. Effectiveness of the safety lancet's sharps injury prevention features.Time frame: At time of testing, up to 90 minutes

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • Chicago office

    Chicago, Illinois

  • Boston office

    Boston, Massachusetts

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.